Speakers
Eduardo Bruno Martins
Vice President - Clinical Development
Abbvie
Day Two
Thursday May 6 2021
11:00 am | Combination Therapy for HBV Cure
Yuchun Nie
Senior scientist
Aligos Therapeutics
Day One
Wednesday May 5 2021
1:30 pm | A Robust HBV Infected 3D Culture Model for Evaluate Efficacy Of Galnac-Oligos In Vitro
Gaston Picchio
Chief Development Officer
Arbutus Biopharma
Day One
Wednesday May 5 2021
4:00 pm | An RNAi for the Treatment Of Chronic Hepatitis B Infection: Clinical Update
Jinzi Wu
Founder, Chairman and Chief Executive Officer
Ascletis Inc
Day Two
Thursday May 6 2021
9:30 am | Strategy of Building HBV Pipeline Leading to Functional Cure
William Delaney
Chief Scientific Officer
Assembly Biosciences (USA)
Day Two
Thursday May 6 2021
1:00 pm | Targeting HBV Core Protein to Improve Treatment for Chronic Hepatitis B Patients
Stephane Daffis
Scientist II
Gilead Sciences
Day One
Wednesday May 5 2021
9:30 am | Keynote Presentation from Gilead Sciences: Preclinical Development of Toll-like Receptor Agonists for Chronic HBV Infection
Yong-Yuan Zhang
Founder and Chief Science Officer
HBVtech
Day One
Wednesday May 5 2021
11:00 am | Curing Chronic HBV Infection Guided by HBV Infection Biology
Melissa Palmer
Chief Medical Officer
Gannex Pharma Ltd. A wholly owned subsidiary of Ascletis Pharma LLC
Day One
Wednesday May 5 2021
2:00 pm | Managing Potential Drug-Induced Liver Injuries During Clinical Trials for Novel HBV Therapies
Chari Cohen
Senior Vice President
Hepatitis B Foundation
Day Two
Thursday May 6 2021
2:30 pm | The Patient Perspective on Hepatitis B Treatment, Cure & Clinical Trial Participation
Paul Desmond
Coordinator
Hepatitis B Positive Trust
Day Two
Thursday May 6 2021
3:00 pm | Panel Discussion: Discuss How We Can Identify Patient Populations for a Variety of Chronic HBV Therapeutic Trials
2:00 pm | Global Barriers to a HBV Cure Roll-Out
Marco Lepore
Head of Discovery Research
Immunocore Ltd
Day One
Wednesday May 5 2021
10:00 am | Understanding the immune response to HBV in chronically infected patients: Implication for immunotherapy design
Patricia Mendez
Vice President - Clinical Development
Immunocore Ltd
Day Two
Thursday May 6 2021
3:00 pm | Panel Discussion: Discuss How We Can Identify Patient Populations for a Variety of Chronic HBV Therapeutic Trials
Sarah Leonard
Group Leader
Immunocore Ltd.
Day One
Wednesday May 5 2021
3:30 pm | Immtav® Molecules for The Treatment Of Hepatitis B
Andrew Vaillant
Chief Scientific Officer
Replicor Inc.
Day Two
Thursday May 6 2021
12:00 pm | HBsAg, Subviral Particles and Their Clearance in Establishing Functional Cure of Chronic HBV Infection
David Anderson
Chief Scientific Officer
VBI Vaccines Inc.
Day Two
Thursday May 6 2021
10:00 am | Role of a Vaccine Immunotherapeutic in Combination Therapy to Achieve Functional Cure for Chronic HBV Infection
Stephan Urban
Professor
University Hospital of Heidelberg
Day One
Wednesday May 5 2021
11:30 am | Towards a Curative Therapy for Hepatitis B and D Co-Infected Patients: A Pivotal Role for Entry Inhibition with Myrcludex B/ Bulevirtide Alone or in Combination with Peg-IFN-alpha
Haitao Guo
Professor
University of Pittsburgh
Day One
Wednesday May 5 2021
12:00 pm | Harnessing New Knowledge of HBV Replication Cycle for Antiviral Discovery
Tom Evans
Chief Scientific Officer
Vaccitech
Day One
Wednesday May 5 2021
2:30 pm | Development of a Therapeutic Vaccine for Hepatitis B
Day Two
Thursday May 6 2021
12:30 pm | Development of a Therapeutic Vaccine for Hepatitis B
Pietro Scalfaro
Chief Medical Officer
ENYO Pharma
Day Two
Thursday May 6 2021
9:00 am | Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B
Ventzislav Vassilev
Program Development Lead, Chronic Hepatitis B Immunotherapy
GSK
Day One
Wednesday May 5 2021
9:15 am | Opening Remarks from Chairperson
Day Two
Thursday May 6 2021